Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide

02 Feb 2011

• By The Pink Sheet Daily

Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.

Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide

More from Archive

More from Pink Sheet